MX2012003042A - Uso de guaifenesina para inhibir la secrecion de mucina. - Google Patents

Uso de guaifenesina para inhibir la secrecion de mucina.

Info

Publication number
MX2012003042A
MX2012003042A MX2012003042A MX2012003042A MX2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A MX 2012003042 A MX2012003042 A MX 2012003042A
Authority
MX
Mexico
Prior art keywords
guaifenesin
mucin secretion
inhibiting mucin
inhibiting
secretion
Prior art date
Application number
MX2012003042A
Other languages
English (en)
Spanish (es)
Inventor
Helmut Albrecht
Kim K Chul
Jeanclare Seagrave
Bruce K Rubin
Gail Solomon
Original Assignee
Reckitt Benckiser Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser Llc filed Critical Reckitt Benckiser Llc
Publication of MX2012003042A publication Critical patent/MX2012003042A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012003042A 2009-09-12 2010-09-13 Uso de guaifenesina para inhibir la secrecion de mucina. MX2012003042A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
MX2012003042A true MX2012003042A (es) 2012-05-29

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003042A MX2012003042A (es) 2009-09-12 2010-09-13 Uso de guaifenesina para inhibir la secrecion de mucina.

Country Status (12)

Country Link
EP (1) EP2475360A1 (ja)
JP (1) JP2013504554A (ja)
KR (1) KR20120068889A (ja)
CN (1) CN102596189A (ja)
AU (1) AU2010294008B2 (ja)
BR (1) BR112012005517A2 (ja)
CA (1) CA2773611A1 (ja)
MX (1) MX2012003042A (ja)
MY (1) MY161187A (ja)
RU (1) RU2012114323A (ja)
WO (1) WO2011030163A1 (ja)
ZA (1) ZA201201822B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619321A (zh) * 2012-04-06 2015-05-13 Uab研究基金会 用于增加cftr活性的方法
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
JP2005519923A (ja) * 2002-02-04 2005-07-07 ファルマシア・コーポレーション シクロオキシゲナーゼ−２選択的阻害剤ならびに風邪および咳止め薬の組み合わせを用いる風邪および咳の治療ならびにそれらの組成物
KR20060056444A (ko) * 2003-06-19 2006-05-24 제내라 코포레이션 뮤신 합성 억제제
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Also Published As

Publication number Publication date
MY161187A (en) 2017-04-14
BR112012005517A2 (pt) 2016-04-19
ZA201201822B (en) 2013-05-29
CA2773611A1 (en) 2011-03-17
RU2012114323A (ru) 2013-10-20
KR20120068889A (ko) 2012-06-27
EP2475360A1 (en) 2012-07-18
JP2013504554A (ja) 2013-02-07
CN102596189A (zh) 2012-07-18
WO2011030163A1 (en) 2011-03-17
AU2010294008B2 (en) 2014-08-14
AU2010294008A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
HK1247133A1 (zh) 低醚組合物及輸送裝置
GB2469580B (en) Delivery method and compositions
EP2231133A4 (en) METHOD AND COMPOSITION FOR THE ADMINISTRATION OF RESVERATROL AND PTEROSTILS
HK1170679A1 (en) Compositions and methods for drug delivery
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
PL2512236T3 (pl) Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)
EP2643045A4 (en) THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
EP2435057A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE LIPID COMPOSITION
EP2504025A4 (en) COMPOSITIONS AND METHODS USING SERRATIA PEPTIDASE FOR INHIBITING AND TREATING BIOFILMS ASSOCIATED WITH PARTICULAR SUFFERING
EP2442655A4 (en) COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
HK1166280A1 (en) Composition for treatment of tuberculosis
ZA201404187B (en) Compositions and methods for treating dental conditions
EP2470019A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS
PL2385029T3 (pl) Kompozycje i sposób cementowania odwiertów
IN2014CN04634A (ja)
HK1173373A1 (en) Method and composition for synchronizing time of insemination
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
EP2588132A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
HUE042907T2 (hu) Szfingozin 1 típusú inhibitorok és eljárás azok elõállítására és alkalmazásaik
HK1168511A1 (en) Anti-oxidant composition
EP2465512A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING PAIN
ZA201203060B (en) Composition and method of delivery
EP2694098A4 (en) ORAL ENZYME COMPOSITIONS FOR INTESTINAL ADMINISTRATION
SG10201907649QA (en) Preventive or therapeutic agent for fibrosis
IL213105A0 (en) Dipeptidyl peptidase iv inhibitors